'Extreme duplication' in the USFDA adverse events reporting system database

被引：55
|
作者：
Reich, Lester
机构：
[1] Pfrizer Inc, Risk Management Strategy, Safety & Risk Management, New York, NY 10017 USA
[2] NYU, Dept Med, Sch Med, New York, NY USA
[3] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA
[4] New York Med Coll, Dept Community & Prevent Med, Valhalla, NY 10595 USA
[5] Brunel Univ, Sch Informat Comp & Math, London, England
来源：
DRUG SAFETY | 2007年 / 30卷 / 06期
关键词：
D O I：
10.2165/00002018-200730060-00009
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：551 / 554
页数：4
相关论文
共 50 条
  • [1] ‘Extreme Duplication’ in the US FDA Adverse Events Reporting System Database
    Manfred Hauben
    Lester Reich
    James De Micco
    Katherine Kim
    [J]. Drug Safety, 2007, 30 : 551 - 554
  • [2] Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Elsa
    [J]. ASIAN JOURNAL OF PSYCHIATRY, 2017, 30 : 152 - 156
  • [3] NOVEL ADVERSE EVENTS OF CGRP RECEPTOR ANTAGONISTS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Sangnure, A.
    Das, A.
    Sajjan, S.
    Ac, R.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S372 - S373
  • [4] EMPAGLIFLOZIN INDUCED PANCREATITIS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Sharma, V
    Viswam S, K.
    Ravindra, Reddy N.
    Chacko, S.
    Bellapu, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S592 - S593
  • [5] Vedolizumab associated haematochezia: A disproportionality analysis in USFDA adverse event reporting system database
    Bellapu, Anusha
    Viswam, Subeesh K.
    Sharma, Vasista
    Chacko, Stephy T.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 464 - 464
  • [6] MEPOLIZUMAB INDUCED MYALGIA: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Chacko, S.
    Viswam, K. S.
    Reddy, Ravindra N.
    Sharma, V
    Bellapu, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S882 - S882
  • [7] BEVACIZUMAB INDUCED PULMONARY EMBOLISM: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Bellapu, A.
    Viswam, K. S.
    Reddy, Ravindra N.
    Chacko, S.
    Sharma, V
    [J]. VALUE IN HEALTH, 2019, 22 : S883 - S884
  • [8] POTENTIAL ASSOCIATION OF REMDESIVIR AND HYPERKALEMIA: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Das, A.
    Vajapu, M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S172 - S172
  • [9] Data mining in the USFDA adverse event reporting system (AERS): Depression/suicidality and unexpected adverse events with anti obesity drugs
    Patrick DeLisle, F.
    Hornbuckle, Kenneth
    Noel, Rebecca
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S21 - S21
  • [10] Immune checkpoint inhibitors induced miller fisher syndrome: A disproportionality analysis in USFDA adverse event reporting system database
    Pawar, Mansi
    Lukose, Lipin
    Viswam, Subeesh K.
    Salim, Mohammed K. T.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 634 - 635
12345